Second Sight to Present at the 19 th Annual Rodman & Renshaw Global
Investment Conference in New York on September 12 th
Second Sight Medical Products, Inc. (NASDAQ:EYES) ("Second Sight" or "the Company"), a developer, manufacturer and marketer of
implantable visual prosthetics to provide useful vision to blind patients, today announced that Dr. Robert Greenberg, Chairman,
will host one-on-one meetings throughout the day with investors and present at the Rodman & Renshaw 19th Annual Global
Investment Conference as follows:
| Date: |
|
Tuesday, September 12, 2017 |
| Time: |
|
1:45 p.m. Eastern Daylight Time |
| Location: |
|
Lotte New York Palace Hotel – 455 Madison Ave, New York, NY 10022 |
|
|
|
The presentation will be webcast and available following the live presentation. The webcast can be viewed at: http://wsw.com/webcast/rrshq27/eyes
Registration is mandatory. For more information about the conference or to schedule a one-on-one meeting, please contact your
Rodman & Renshaw representative.
About the Argus II Retinal Prosthesis System
Second Sight's Argus II System provides electrical stimulation that bypasses the defunct retinal cells and stimulates remaining
viable cells inducing visual perception in individuals with severe to profound Retinitis Pigmentosa. The Argus II works by
converting images captured by a miniature video camera mounted on the patient's glasses into a series of small electrical pulses,
which are transmitted wirelessly to an array of electrodes implanted on the surface of the retina. These pulses stimulate the
retina's remaining cells, intending to result in the perception of patterns of light in the brain. The patient must learn to
interpret these visual patterns, having the potential to regain some visual function. The Argus II was the first artificial retina
to receive widespread commercial approval, and is offered at approved centers in Canada, France, Germany, Italy, Russia, Saudi
Arabia, South Korea, Spain, Taiwan, Turkey, United Kingdom, and the U.S.
About the Orion Visual Cortical Prosthesis System
Second Sight, the manufacturer of the Argus II Retinal Prosthesis System (Argus II), has developed a new device, the Orion. A
proof-of-concept clinical trial demonstrating the viability of stimulation of the human visual cortex with a commercially available
device from a different manufacturer began in Q4 2016 at UCLA. First-in-human clinical studies with the Orion are planned in 2017.
Like the Argus II, the idea behind Second Sight’s Orion is to convert images captured by a miniature video camera mounted on the
patient's glasses into a series of small electrical pulses. The Orion is designed to transmit these electrical pulses wirelessly to
an array of electrodes implanted on the surface of the visual cortex, intended to result in the perception of patterns of light. By
bypassing the retina and optic nerve and directly stimulating the visual cortex, a cortical prosthesis system has the potential to
restore useful vision to patients completely blinded due to many reasons, including glaucoma, diabetic retinopathy, or forms of
cancer and trauma.
About Second Sight
Second Sight's mission is to develop, manufacture and market innovative implantable visual prosthetics to enable blind
individuals to achieve greater independence. Second Sight has developed and now manufactures and markets the Argus® II Retinal
Prosthesis System. Enrollment has been completed in a feasibility trial to test the safety and utility of the Argus II in
individuals with Dry Age-Related Macular Degeneration. Second Sight is also developing the Orion™ Visual Cortical Prosthesis to
restore some vision to individuals who are blind due to causes other than preventable or treatable conditions. U.S. Headquarters
are in Sylmar, California, and European Headquarters are in Lausanne, Switzerland. For more information, visit www.secondsight.com.
Safe Harbor
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange and Exchange Act of 1934, as amended, which are intended to be covered by the
"safe harbor" created by those sections. All statements in this release that are not based on historical fact are "forward looking
statements." These statements may be identified by words such as "estimates," "anticipates," "projects," "plans," or "planned,"
"seeks," "may," "will," "expects," "intends," "believes," "should" and similar expressions or the negative versions thereof and
which also may be identified by their context. All statements that address operating performance or events or developments that
Second Sight expects or anticipates will occur in the future, such as stated objectives or goals, or that are not otherwise
historical facts, are forward-looking statements. While management has based any forward looking statements included in this
release on its current expectations, the information on which such expectations were based may change. Forward-looking statements
involve inherent risks and uncertainties which could cause actual results to differ materially from those in the forward-looking
statements, as a result of various factors including those risks and uncertainties described in the Risk Factors and in
Management's Discussion and Analysis of Financial Condition and Results of Operations sections of our Annual Report on Form 10-K as
filed on March 16, 2017, and our other reports filed from time to time with the Securities and Exchange Commission.
We urge you to consider those risks and uncertainties in evaluating our forward-looking statements. We caution readers not to place
undue reliance upon any such forward-looking statements, which speak only as of the date made. Except as otherwise required by the
federal securities laws, we disclaim any obligation or undertaking to publicly release any updates or revisions to any
forward-looking statement contained herein (or elsewhere) to reflect any change in our expectations with regard thereto or any
change in events, conditions or circumstances on which any such statement is based.
Institutional Investors
In-Site Communications, Inc.
Lisa Wilson, 212-452-2793
President
lwilson@insitecony.com
or
Individual Investors
MZ North America
Greg Falesnik, 949-385-6449
Managing Director
greg.falesnik@mzgroup.us
View source version on businesswire.com: http://www.businesswire.com/news/home/20170905005340/en/